Results 121 to 130 of about 6,658 (202)

A nucleic acid labeling chemistry reveals surface DNA on exosomes. [PDF]

Proc Natl Acad Sci U S A
Bošković F, Dutta Gupta P, Zhang J, Krishnan Y, Szostak JW.   +4 more
europepmc   +1 more source

Targeting the DNA-repair chromatin-modifier protein SMYD3 as a novel epigenetics-based therapy for gastric cancer. [PDF]

J Exp Clin Cancer Res
De Marco K, Latrofa M, Forte G, Lepore Signorile M, Di Nicola E, Sanese P, Fasano C, Disciglio V, Candela E, Coletta S, Grossi V, Simone C.   +11 more
europepmc   +1 more source

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors. [PDF]

RSC Adv
Rani D, Plebanski M, Chatterjee T.
europepmc   +1 more source

Poly(ADP-ribose) polymerase inhibitor maintenance therapy in ovarian cancer: a single-center retrospective study. [PDF]

Front Oncol
Pence S, Dyson K, Waters K, Elliott JO, Rath K, Pierce S, Harper A, Calo C, Clements AE.   +8 more
europepmc   +1 more source

Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine. [PDF]

J Clin Med
Kawczak P, Bączek T.
europepmc   +1 more source

Limited inclusion in clinical trials and access to poly (ADP-ribose) polymerase inhibitors in racial and ethnic minority patients with cancer: a narrative review. [PDF]

Oncologist
Swearingen A, Audu B, Hamidu A, Mustapha A, Oguntayo A, Yahya A, Bello A, Butler R, Halliday D, Bowe S, Jordan S, Hew K, Pinto A, Castillo RP, Reis IM, George S, Schlumbrecht M.   +16 more
europepmc   +1 more source

Maintenance therapy in gynecologic malignancies: Current and future state. [PDF]

Cancer
Widick PC, Wright AA, Liu JF.
europepmc   +1 more source

PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers. [PDF]

Int J Mol Sci
Dos Santos ES, Cicilini AL, Simões MFE, Baz M, Caputo SM, Rouleau E.   +5 more
europepmc   +1 more source

HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications. [PDF]

Clin Cancer Res
Banda K, Davies HR, Kumar Y, Memari Y, Degasperi A, Radke M, Rodriguez I, Gooley TA, Katz R, Menghi F, Harding T, Lin K, Liu ET, Nik-Zainal S, Swisher EM.   +14 more
europepmc   +1 more source

Off-target drug repurposing for rare and ultra-rare cancers: towards a scalable therapeutic framework. [PDF]

Front Genet
Premaratne G, Ameratunga M.
europepmc   +1 more source